Moleculin Biotech, Inc. – NASDAQ:MBRX

Add to watchlist

$0.59

-1.05

-64.24%

Market closed

Open in 2 days

-62.07%

month

-62.07%

quarter

+132.39%

year

Market Cap	4.84M
Enterprise value	N/A

P/E	-0.87
EV/Sales	N/A
EV/EBITDA	0.40
Price/Sales	N/A
Price/Book	0.49
PEG ratio	0.01
EPS	-12.99

Revenue	N/A
EBITDA	-27.89M
Income	-26.82M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Moleculin Biotech, Inc. (NASDAQ:MBRX): Profit margin
Jun 2023	0	-5.97M
Sep 2023	0	-5.60M
Dec 2023	406K	-10.26M	-2529.31%
Mar 2024	0	-4.97M

Moleculin Biotech Financials Estimate

Q Y

Moleculin Biotech, Inc. (NASDAQ:MBRX): Analyst Estimates
2025	34.43M	-31.37M	-91.11%
2026	71.41M	-34.53M	-48.35%
2027	41.05M	3.23M	7.87%
2028	85.27M	13.97M	16.39%

Analysts Price target
Financials & Ratios estimates

Moleculin Biotech, Inc. (NASDAQ:MBRX): Debt to assets
Jun 2023	47115000	6.84M	14.53%
Sep 2023	39523000	4.38M	11.09%
Dec 2023	38217000	12.14M	31.78%
Mar 2024	30845000	9.25M	30.01%

Moleculin Biotech, Inc. (NASDAQ:MBRX): Cash Flow
Jun 2023	-5.12M	-15K	49
Sep 2023	-7.55M	-28K	-4
Dec 2023	-5.40M	-81K	4.46K
Mar 2024	-6.71M	0	0

Moleculin Biotech alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Moleculin Biotech, Inc. (NASDAQ:MBRX): Employee count
Aug 2023	15
Sep 2023	15
Oct 2023	15
Nov 2023	15
Dec 2023	15
Jan 2024	15
Feb 2024	15
Mar 2024	18
Apr 2024	18
May 2024	18
Jun 2024	18
Jul 2024	18

Moleculin Biotech
Hedge Funds Holdings Q1 2023

5.54% -5.60%

of MBRX is owned by hedge funds

14 -10

hedge funds hold MBRX stock

1.48M -1.50M

shares is hold by hedge funds

MBRX hedge funds holdings changes

Moleculin Biotech
Insider Trading

Moleculin Biotech, Inc. (NASDAQ:MBRX): Insider trades (number of shares)
Period	Buy	Sel
Dec 2023	231883	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	16 Jun 2024	FOSTER JONATHAN P. officer: Chief Financial Officer officer: Chief Financial Officer	Restricted Stock Units	834	N/A	N/A
Option	16 Jun 2024	FOSTER JONATHAN P. officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock	834	N/A	N/A
Option	16 Jun 2024	KLEMP WALTER V director, officer..	Restricted Stock Units	1,667	N/A	N/A
Option	16 Jun 2024	KLEMP WALTER V director, officer..	Restricted Stock Units	1,667	N/A	N/A
Option	16 Jun 2024	KLEMP WALTER V director, officer..	Common Stock	1,667	N/A	N/A
Option	16 Jun 2024	KLEMP WALTER V director, officer..	Common Stock	1,667	N/A	N/A
Purchase	26 Dec 2023	FOSTER JONATHAN P. officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock	28,986	$0.69	$20,000
Purchase	26 Dec 2023	GEORGE ROBERT E. director director	Common Stock	14,493	$0.69	$10,000
Purchase	26 Dec 2023	KLEMP WALTER V director, officer..	Common Stock	188,404	$0.69	$129,999
Purchase	26 Dec 2023	KLEMP WALTER V director, officer..	Common Stock	188,404	$0.69	$129,999

MBRX insider trading transactions

Moleculin Biotech
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 13 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 25 Mar 2024	Q4 2023 Earnings Call Transcript
Q3 2023 13 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 11 Aug 2023	Q2 2023 Earnings Call Transcript

MBRX earnings call transcripts

Moleculin Biotech
Executives

Insider	Age	Compensation
Mr. Walter V. Klemp (1960) Founder, Chairman, Pres & Chief Executive Officer	65	$778,140
Mr. Jonathan P. Foster CPA (1964) Executive Vice President & Chief Financial Officer	61	$568,610
Dr. Donald H. Picker Ph.D. (1946) Chief Scientific Officer	79	$438,160

Moleculin Biotech
Latest News

Wednesday, 11 December 2024
08:00	Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML Model	prnewswire.com
Monday, 18 November 2024
08:15	New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML	prnewswire.com
Thursday, 14 November 2024
08:15	Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025	prnewswire.com
Tuesday, 12 November 2024
08:00	Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML)	prnewswire.com
Monday, 11 November 2024
11:17	Moleculin Biotech, Inc. (MBRX) Q3 2024 Earnings Call Transcript	seekingalpha.com
07:05	Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update	prnewswire.com
Tuesday, 5 November 2024
09:00	Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast	prnewswire.com
Monday, 4 November 2024
08:30	Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin	prnewswire.com
Thursday, 17 October 2024
08:40	Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now Available	prnewswire.com
Monday, 7 October 2024
08:30	Moleculin to Host Virtual Acute Myeloid Leukemia KOL Event on October 14, 2024	prnewswire.com
Friday, 4 October 2024
09:00	Moleculin to Present at Two Upcoming Investor Conferences	prnewswire.com
Monday, 23 September 2024
08:00	Moleculin Announces Positive In Vivo Efficacy Data of Annamycin in Orthotopic and Experimental Lung Metastatic Models of Sarcoma	prnewswire.com
Monday, 16 September 2024
08:30	Moleculin Participates in Virtual Investor "What this Means" Segment	prnewswire.com
Monday, 9 September 2024
08:15	Moleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma	prnewswire.com
Tuesday, 3 September 2024
09:15	Moleculin to Present at the H.C. Wainwright 26th Annual Global Investment Conference	prnewswire.com
Monday, 26 August 2024
08:30	Moleculin to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar	prnewswire.com
Monday, 19 August 2024
16:05	Moleculin Announces Closing of up to $16.5 Million Public Offering	prnewswire.com
Wednesday, 14 August 2024
08:05	Moleculin Reports Second Quarter 2024 Financial Results and Provides Corporate Update	prnewswire.com
Monday, 5 August 2024
09:05	Moleculin to Host Webcast Presentation to Discuss Recently Announced Plans for MIRACLE Phase 3 Pivotal Trial Tuesday, August 6, 2024 at 8:30 AM ET	prnewswire.com
Thursday, 1 August 2024
08:30	Moleculin Announces Plans for MIRACLE Phase 3 Pivotal Trial	prnewswire.com
Wednesday, 10 July 2024
08:30	Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML	prnewswire.com
Friday, 14 June 2024
08:00	Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial	prnewswire.com
Wednesday, 12 June 2024
09:00	Moleculin to Present at the Virtual Investor Pitch Conference	prnewswire.com
Wednesday, 5 June 2024
08:55	Moleculin to Participate in the Virtual Investor Lunch Break Series	prnewswire.com
Thursday, 16 May 2024
08:32	Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress	prnewswire.com
Wednesday, 15 May 2024
08:38	Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)	prnewswire.com
Monday, 13 May 2024
11:44	Moleculin Biotech, Inc. (MBRX) Q1 2024 Earnings Call Transcript	seekingalpha.com
07:30	Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update	prnewswire.com
Thursday, 9 May 2024
08:30	Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin	prnewswire.com
Wednesday, 8 May 2024
08:45	Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast	PRNewsWire

Frequently Asked Questions (FAQ)

What's the price of Moleculin Biotech stock today?

One share of Moleculin Biotech stock can currently be purchased for approximately $0.59.
When is Moleculin Biotech's next earnings date?

Unfortunately, Moleculin Biotech's (MBRX) next earnings date is currently unknown.
Does Moleculin Biotech pay dividends?

No, Moleculin Biotech does not pay dividends.
How much money does Moleculin Biotech make?

Moleculin Biotech has a market capitalization of 4.84M.
What is Moleculin Biotech's stock symbol?

Moleculin Biotech, Inc. is traded on the NASDAQ under the ticker symbol "MBRX".
What is Moleculin Biotech's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Moleculin Biotech?

Shares of Moleculin Biotech can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Moleculin Biotech's key executives?
Moleculin Biotech's management team includes the following people:
- Mr. Walter V. Klemp Founder, Chairman, Pres & Chief Executive Officer(age: 65, pay: $778,140)
- Mr. Jonathan P. Foster CPA Executive Vice President & Chief Financial Officer(age: 61, pay: $568,610)
- Dr. Donald H. Picker Ph.D. Chief Scientific Officer(age: 79, pay: $438,160)
Is Moleculin Biotech founder-led company?

Yes, Moleculin Biotech is a company led by its founder Mr. Walter V. Klemp.
How many employees does Moleculin Biotech have?

As Jul 2024, Moleculin Biotech employs 18 workers.
When Moleculin Biotech went public?

Moleculin Biotech, Inc. is publicly traded company for more then 9 years since IPO on 2 Jun 2016.
What is Moleculin Biotech's official website?

The official website for Moleculin Biotech is moleculin.com.
Where are Moleculin Biotech's headquarters?

Moleculin Biotech is headquartered at 5300 Memorial Drive, Houston, TX.
How can i contact Moleculin Biotech?

Moleculin Biotech's mailing address is 5300 Memorial Drive, Houston, TX and company can be reached via phone at +7 133005160.

Moleculin Biotech, Inc.

moleculin.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.

+7 133005160

5300 Memorial Drive
Houston, TX 77007

CIK: 0001659617
ISIN: US60855D2009
CUSIP: 60855D200